Comparison of magnesium given by mouth to magnesium given through the vein to treat patients with low blood magnesium

ISRCTN ISRCTN16067597
DOI https://doi.org/10.1186/ISRCTN16067597
Submission date
23/06/2022
Registration date
25/08/2022
Last edited
25/08/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Hypomagnesemia is when the amount of magnesium in the blood is too low. This can cause nausea and vomiting, sleepiness, muscle weakness, spasms, or tremors. This study will compare treatments for hypomagnesemia, comparing magnesium given by mouth to magnesium given through the vein in its ability to increase the blood magnesium level.

Who can participate?
Adult patients can participate if they are hospitalized and have a low magnesium level, are not taking certain medications (proton pump inhibitors, diuretic use), do not have kidney or intestinal problems, do not have severe infections, are not pregnant, and do not have heart problems happening at the same time.

What does the study involve?
Participants will be allocated to one of three groups, with an equal chance of being in each group (like tossing a coin). Participants in the first group will receive magnesium given by mouth, participants in the second group will receive magnesium given through injection into the vein at a normal rate, and participants in the third group will receive magnesium given through injection into the vein at a slow rate.

What are the possible benefits and risks of participating?
The possible benefits of participating to the individual include potential avoidance of another vein medication. The benefits to society include better understanding

Where is the study run from?
Riverside University Health Systems - Medical Center (USA)

When is the study starting and how long is it expected to run for?
June 2015 to September 2017

Who is funding the study?
Riverside University Health Systems - Medical Center (USA)

Who is the main contact?
Dr Alexander Friedman, alex.friedman@ruhealth.org

Contact information

Dr Alexander Friedman
Principal Investigator

26520 Cactus Ave
Moreno Valley
92555
United States of America

ORCiD logoORCID ID 0000-0001-5486-6852
Phone +1 9514864000
Email alex.friedman@ruhealth.org

Study information

Study designRandomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet 41970_PIS_Consent_English.pdf
Scientific titleComparison of oral and intravenous magnesium repletion in patients with hypomagnesemia: a randomized controlled trial
Study objectivesRepletion with intravenous magnesium is non inferior to oral magnesium in raising serum magnesium level for mild to moderate hypomagnesemia
Ethics approval(s)Approved 14/12/2015, Riverside University Health System Medical Center (RUHSMC) IRB (26520 Cactus Ave, Moreno Valley, CA 92555; +1 951 486 4098; IRB@RUhealth.org)
Health condition(s) or problem(s) studiedHypomagnesemia
InterventionParticipants will be randomized into three groups. The randomization process will involve randomly generated numbers placed in sealed envelopes. Group 1 received magnesium oxide (MgOx) 400 mg tabs: 1600 mg, followed by 800 mg 4 h later. Group 2 received magnesium sulfate (MgSO4) 2 g IV infused over 2 . Group 3 was administered magnesium sulfate (MgSO4) 2 g IV, infused over 6 h.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)magnesium sulfate, magnesium oxide
Primary outcome measureAbsolute serum magnesium level measured from blood samples collected at the time of enrollment and between 18 and 30 h after initiation of repletion
Secondary outcome measuresThe relative rise in serum magnesium level measured from blood samples collected at the time of enrollment and between 18 and 30 h after initiation of repletion
Overall study start date01/06/2015
Completion date30/09/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants120
Total final enrolment112
Key inclusion criteria1. Inpatient at the participating medical center
2. Aged >18 years
3. Serum magnesium between 1.2 and 1.7 mg/dl
Key exclusion criteria1. Proton pump inhibitor (PPI) use
2. Concomitant diuretic use
3. Acute or chronic renal insufficiency
4. Active myocardial infarction
5. Eclampsia or preeclampsia
6. Pregnancy
7. Incarcerated status
8. Unable to tolerate oral intake
9. History of bowel surgery
10. Active diarrhea
11. Concomitant chemotherapy
12. Severe sepsis
13. Prior enrollment in the study
Date of first enrolment10/07/2015
Date of final enrolment30/09/2017

Locations

Countries of recruitment

  • United States of America

Study participating centre

Riverside University Health System Medical Center
26520 Cactus Ave
Moreno Valley
92555
United States of America

Sponsor information

Riverside University Health System - Medical Center
Hospital/treatment centre

26520 Cactus Ave
Moreno Valley
92555
United States of America

Phone +1 9514864000
Email alex.friedman@ruhealth.org
Website http://www.ruhealth.org/en-us
ROR logo "ROR" https://ror.org/020448x84

Funders

Funder type

Hospital/treatment centre

Riverside University Health System - Medical Center

No information available

Results and Publications

Intention to publish date01/07/2022
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a peer reviewed medical journal
IPD sharing planThe datasets generated during and/or analyzed during the current study are/will be available upon request from Dr Alexander Friedman (alex.friedman@ruhealth.org).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet Informed consent - English language 25/08/2022 No Yes
Participant information sheet Informed consent - Spanish language 25/08/2022 No Yes
Protocol file 25/08/2022 No No

Additional files

41970_Protocol.pdf
41970_PIS_Consent_Spanish.pdf
Informed consent - Spanish language
41970_PIS_Consent_English.pdf
Informed consent - English language

Editorial Notes

25/08/2022: Trial’s existence confirmed by Riverside University Health System Medical Center (RUHSMC) IRB.